Myriad Genetics Earnings: Volatility Ahead

Myriad Genetics earnings report due Tuesday; analysts predict 3.3% revenue growth, following last quarters flat performance. Despite missing revenue targets in the past, peers like Moderna and Biogen have shown strength, with Modernas revenues surging 260% and Biogens shares jumping 3.2%. Myriads stock is currently trading at $4.53, below the $7.42 price target. Expect market volatility if growth is delivered, potentially lifting the stock price towards analyst hopes. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/3bbff0f8699a0162